Johan van der Vlag and Tom Nijenhuis, theme Renal disorders, received this grant for their joint research project “Targeting a novel paracrine signaling pathway between glomerular endothelium and podocytes to treat glomerular injury”.
In patients with rare kidney filter (glomerular) disorders, glomerular injury leads to urinary protein leakage and chronic kidney disease (CKD). Novel therapies to treat glomerular disease or the ensuing progressive CKD have not emerged during the last decade. Thus, there is an unmet need for novel treatment targets, which can be translated into clinically applicable therapy at short term.It is increasingly recognized that paracrine signaling between glomerular endothelial cells and podocytes is crucial to glomerular integrity. Based on preliminary data from their laboratory, Van der Vlag and Nijenhuis hypothesized that nitric oxide (NO) produced by the endothelium activates a podocyte signaling pathway crucial to maintain podocyte viability. This novel paracrine glomerular endothelium-to-podocyte pathway could be therapeutically targeted by repurposing sGC stimulators/activators like Riociguat®.
Johan van der Vlag heads the Nephrology Research Laboratory and, fueled by clinical research questions, focuses on glomerular diseases and (transplantation) immunology. Tom Nijenhuis, internist-nephrologist, specializes in rare kidney disorders.
Lowlands Science call for projects17 February 2020
Researchers pay attention! Lowlands is looking for research teams to participate in Lowlands Science 2020. It’s a great way to reach a large audience, do unique experiments with and on them, and to have a memorable experience with your colleagues.Read more
Five ZonMw ‘Off Road’ grants for Radboudumc researchers17 February 2020
Benoit Besson, Annemarie Boleij, Jonne Doorduin, Jorik Nonnekes and Sara Roig Merino have each received an ZonMw ‘Off Road’ grant of €100,000. The grants are intended for biomedical health researchers who dare to go off the beaten track in their search for new insights and unexpected breakthroughs.Read more
KNAW Early Career Award for Geert Litjens13 February 2020
Twelve young researchers received the Early Career Award from KNAW on 4 february. One of them is RIHS researcher Geert Litjens. The Award is aimed at researchers in the Netherlands at the start of their career who are capable of developing innovative and original research ideas.Read more
Interactive career day for Postdocs and PhD candidates13 February 2020
45 Postdocs and PhD candidates attended the first Interactive career day organised by Janssen Pharmaceutica, to learn more about career perspectives and R&D activities that on the longer term can lead to ideas and potential future collaboration.Read more
SPL Medical starts clinical trial with contrast agent ferrotran11 February 2020
SPL Medical is starting an international registration study for its contrast agent Ferrotran. The study is being conducted in ten hospitals in Germany, Switzerland and the Netherlands. RIHS researcher Jelle Barentsz discovered the value of this drug in patients with lymph node metastases.Read more